Zevra Therapeutics (ZVRA) Operating Income (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Operating Income of $52.1 million for Q1 2026, up 459.81% on a QoQ basis from $9.3 million in Q4 2025, and up 1072.51% year-over-year from $4.4 million in Q1 2025.
Zevra Therapeutics (ZVRA) Operating Income (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Operating Income history runs 13 years deep, the most recent figure standing at $52.1 million for Q1 2026.
- Quarterly Operating Income rose 1072.51% year-over-year to $52.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (up 92.44% YoY) and the FY2025 annual result came in at -$62.9 million, up 27.65% from the prior year.
- Operating Income was $52.1 million for Q1 2026 at Zevra Therapeutics, up from $9.3 million in the prior quarter.
- Across five years, Operating Income topped out at $52.1 million in Q1 2026 and bottomed at -$71.0 million in Q2 2025.
- A 5-year average of -$11.8 million and a median of -$14.0 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 524.6% — and 2026, when it jumped 1072.51%.
- Zevra Therapeutics' Operating Income stood at -$9.3 million in 2022, then sank by 62.75% to -$15.2 million in 2023, then declined by 1.71% to -$15.4 million in 2024, then surged by 160.42% to $9.3 million in 2025, then surged by 459.81% to $52.1 million in 2026.
- Business Quant data shows ZVRA's Operating Income at $52.1 million in Q1 2026, $9.3 million in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 52.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.15 Mn |
| Dec 31, 2025 | 9.32 Mn |
| Sep 30, 2025 | 4.14 Mn |
| Jun 30, 2025 | -71.04 Mn |
| Mar 31, 2025 | -5.36 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | -27.31 Mn |
| Jun 30, 2024 | -23.80 Mn |
| Mar 31, 2024 | -20.49 Mn |
| Dec 31, 2023 | -15.16 Mn |
| Sep 30, 2023 | -15.36 Mn |
| Jun 30, 2023 | -6.25 Mn |
| Mar 31, 2023 | -12.83 Mn |
| Dec 31, 2022 | -9.31 Mn |
| Sep 30, 2022 | -6.63 Mn |
| Jun 30, 2022 | -24.77 Mn |
| Dec 31, 2021 | -2.84 Mn |
| Sep 30, 2021 | -2.22 Mn |
| Jun 30, 2021 | 5.83 Mn |
| Mar 31, 2021 | 6.96 Mn |